[This corrects the article DOI: 10.3389/fonc.2019.00707.].
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6773977 | PMC |
| http://dx.doi.org/10.3389/fonc.2019.00967 | DOI Listing |
Publication Analysis
Top Keywords
corrigendum pam50
4
pam50 subtypes
4
subtypes baseline
4
baseline residual
4
residual tumors
4
tumors neoadjuvant
4
neoadjuvant trastuzumab-based
4
trastuzumab-based chemotherapy
4
chemotherapy her2-positive
4
her2-positive breast
4
Similar Publications
Corrigendum: Genomic Assays in Node Positive Breast Cancer Patients: A Review.
Front Oncol
April 2021
Department of Internal Medicine, Naef K. Basile Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon.
Article Synopsis
- The text is a correction to a previously published article, identified by its DOI: 10.3389/fonc.2020.609100.
- Corrections typically address errors in the original publication, which could involve data, methodology, or other essential details.
- This highlights the importance of accuracy and transparency in scientific literature for the community's understanding and future research.
Corrigendum: PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution.
Front Oncol
September 2019
Department of Medical Oncology, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain.
[This corrects the article DOI: 10.3389/fonc.2019.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!